TY  - BOOK
AU  - Vargas, Jose D
TI  - Baseline Characteristics of the VANISH Cohort
SN  - 1941-3289
PY  - 2019///
KW  - *Angiotensin II Type 1 Receptor Blockers/tu [Therapeutic Use]
KW  - *Cardiomyopathy, Hypertrophic/dt [Drug Therapy]
KW  - *Mutation
KW  - *Sarcomeres/ge [Genetics]
KW  - *Valsartan/tu [Therapeutic Use]
KW  - Adolescent
KW  - Adult
KW  - Angiotensin II Type 1 Receptor Blockers/ae [Adverse Effects]
KW  - Brazil
KW  - Canada
KW  - Cardiomyopathy, Hypertrophic/di [Diagnosis]
KW  - Cardiomyopathy, Hypertrophic/ge [Genetics]
KW  - Cardiomyopathy, Hypertrophic/pp [Physiopathology]
KW  - Child
KW  - Denmark
KW  - Disease Progression
KW  - Double-Blind Method
KW  - Female
KW  - Genetic Predisposition to Disease
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Phenotype
KW  - Recovery of Function
KW  - Time Factors
KW  - Treatment Outcome
KW  - United States
KW  - Valsartan/ae [Adverse Effects]
KW  - Young Adult
KW  - MedStar Health Research Institute
KW  - Journal Article
N1  - Available online from MWHC library: 2008 - present
N2  - BACKGROUND: The VANISH trial (Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy) targeted young sarcomeric gene mutation carriers with early-stage hypertrophic cardiomyopathy (HCM) to test whether valsartan can modify disease progression. We describe the baseline characteristics of the VANISH cohort and compare to previous trials evaluating angiotensin receptor blockers; CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01912534; CONCLUSIONS: The VANISH cohort is much larger, younger, less heterogeneous, and has less advanced disease than prior angiotensin receptor blocker trials in HCM. Participants had relatively normal functional capacity and mild HCM features. New York Heart Association functional class II symptoms were associated with older age, more prominent imaging abnormalities, and MYH7 variants, suggesting both phenotype and genotype contribute to disease manifestations; METHODS: Applying a randomized, double-blinded, placebo-controlled design, 178 participants with nonobstructive HCM (age, 23.3+/-10.1 years; 61% men) were randomized in the primary cohort and 34 (age, 16.5+/-4.9 years; 50% men) in the exploratory cohort of sarcomeric mutation carriers without left ventricular hypertrophy; RESULTS: In the primary cohort, maximal left ventricular wall thickness was 17+/-4 mm for adults and Z score 7.0+/-4.5 for children. Nineteen percent had late gadolinium enhancement on cardiac magnetic resonance. Mean peak oxygen consumption was 33 mL/kg per minute, and 92% of participants were New York Heart Association functional class I. New York Heart Association class II was associated with older age, MYH7 variants, and more prominent imaging abnormalities. Six previous trials of angiotensin receptor blockers in HCM enrolled a median of 24 patients (range, 19-133) with mean age of 51.2 years; 42% of patients were in New York Heart Association class >=II, and sarcomeric mutations were not required
UR  - https://dx.doi.org/10.1161/CIRCHEARTFAILURE.119.006231
ER  -